Manuela Casula1, Lorenza Scotti2, Elena Tragni3, Luca Merlino4, Giovanni Corrao2, Alberico L Catapano5. 1. Epidemiology and Preventive Pharmacology Centre (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milan, Italy. Electronic address: sefap@unimi.it. 2. Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milano-Bicocca, via Bicocca degli Arcimboldi 8, 20126 Milan, Italy. 3. Epidemiology and Preventive Pharmacology Centre (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milan, Italy. 4. Operative Unit of Territorial Health Services, Region Lombardia, Milan, Italy. 5. Epidemiology and Preventive Pharmacology Centre (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milan, Italy; IRCCS MultiMedica, via Milanese 300, 20099 Sesto S. Giovanni, MI, Italy.
Abstract
BACKGROUND AND AIMS: We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. METHODS: From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. RESULTS: Of 1404 patients, 42.4% were initially treated with a high-efficacy statin. 23.4% of patients showed at least one treatment change. Mean MPR was 68.7% (29.9), and patients showing continued statin use were 47.0%. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95% confidential interval] 2.28 [1.69-3.09]) and at least one lipid test (RR 1.82 [1.31-2.53]). MPR ≥80% was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09-1.51] and rosuvastatin RR 1.21 [1.01-1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12-1.59]), at least one therapy change (RR 1.28 [1.15-1.43]), at least a lipid test (RR 1.26 [1.07-1.49]). A similar pattern was observed for persistence. CONCLUSIONS: This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.
BACKGROUND AND AIMS: We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. METHODS: From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. RESULTS: Of 1404 patients, 42.4% were initially treated with a high-efficacy statin. 23.4% of patients showed at least one treatment change. Mean MPR was 68.7% (29.9), and patients showing continued statin use were 47.0%. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95% confidential interval] 2.28 [1.69-3.09]) and at least one lipid test (RR 1.82 [1.31-2.53]). MPR ≥80% was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09-1.51] and rosuvastatin RR 1.21 [1.01-1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12-1.59]), at least one therapy change (RR 1.28 [1.15-1.43]), at least a lipid test (RR 1.26 [1.07-1.49]). A similar pattern was observed for persistence. CONCLUSIONS: This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.
Authors: Henry N Ginsberg; Jaakko Tuomilehto; G Kees Hovingh; Bertrand Cariou; Raul D Santos; Alan S Brown; Santosh K Sanganalmath; Andrew Koren; Desmond Thompson; Frederick J Raal Journal: Cardiovasc Drugs Ther Date: 2019-02 Impact factor: 3.727
Authors: Miriam Nurm; Anu Reigo; Margit Nõukas; Liis Leitsalu; Tiit Nikopensius; Marili Palover; Tarmo Annilo; Maris Alver; Aet Saar; Toomas Marandi; Tiia Ainla; Andres Metspalu; Tõnu Esko; Neeme Tõnisson Journal: Front Genet Date: 2022-07-19 Impact factor: 4.772
Authors: Leo E Akioyamen; Anna Chu; Jacques Genest; Douglas S Lee; Husam Abdel-Qadir; Cynthia A Jackevicius; Patrick R Lawler; Maneesh Sud; Jacob A Udell; Harindra C Wijeysundera; Dennis T Ko Journal: CJC Open Date: 2022-05-20
Authors: Fatima Rodriguez; Joshua W Knowles; David J Maron; Salim S Virani; Paul A Heidenreich Journal: Am J Cardiol Date: 2018-06-07 Impact factor: 2.778